EP1962835 - TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE USING CHOLESTEROL LOWERING AGENTS AND/OR H3 RECEPTOR ANTAGONIST/INVERSE AGONIST [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 25.02.2011 Database last updated on 31.08.2024 | Most recent event Tooltip | 25.02.2011 | Application deemed to be withdrawn | published on 30.03.2011 [2011/13] | Applicant(s) | For all designated states Schering Corporation 2000 Galloping Hill Road Kenilworth, NJ 07033-0530 / US | [2008/36] | Inventor(s) | 01 /
HWA, Joyce, J. 909 Prospect Street Westfield, NJ 07090 / US | 02 /
VAN HEEK, Margaret 1851 Raritan Road Scotch Plains, NJ 07076 / US | 03 /
DAVIS, Harry, Jr. 64 River Bend Road Berkeley Heights, NJ 07922 / US | [2008/36] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE | [N/P] |
Former [2008/36] | HOFFMANN EITLE Patent- und Rechtsanwälte Arabellastrasse 4 81925 München / DE | Application number, filing date | 06845826.4 | 19.12.2006 | [2008/36] | WO2006US48455 | Priority number, date | US20050752710P | 21.12.2005 Original published format: US 752710 P | US20060787048P | 29.03.2006 Original published format: US 787048 P | US20060836642P | 09.08.2006 Original published format: US 836642 P | US20060855178P | 30.10.2006 Original published format: US 855178 P | [2008/36] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2007075702 | Date: | 05.07.2007 | Language: | EN | [2007/27] | Type: | A2 Application without search report | No.: | EP1962835 | Date: | 03.09.2008 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.07.2007 takes the place of the publication of the European patent application. | [2008/36] | Search report(s) | International search report - published on: | EP | 16.08.2007 | Classification | IPC: | A61K31/397, A61K31/445, A61P3/06, A61P3/10 | [2008/36] | CPC: |
A61K31/397 (EP,US);
A61K31/445 (EP,US);
A61K31/7052 (EP,US);
A61K45/06 (EP,US);
A61P1/16 (EP);
A61P3/04 (EP);
| C-Set: |
A61K31/397, A61K2300/00 (EP,US);
A61K31/445, A61K2300/00 (US,EP);
A61K31/7052, A61K2300/00 (US,EP)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/36] | Extension states | AL | 28.03.2008 | BA | 28.03.2008 | HR | 28.03.2008 | MK | 28.03.2008 | RS | 28.03.2008 | Title | German: | BEHANDLUNG NICHT ALKOHOLINDUZIERTER FETTLEBER MITTELS CHOLESTERINSENKENDEN MITTELN UND/ODER H3-REZEPTOR-ANTAGONISTEN ODER -INVERSAGONISTEN | [2008/36] | English: | TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE USING CHOLESTEROL LOWERING AGENTS AND/OR H3 RECEPTOR ANTAGONIST/INVERSE AGONIST | [2008/36] | French: | TRAITEMENT DE LA STEATOSE HEPATIQUE NON ALCOOLIQUE AU MOYEN D'AGENTS HYPOCHOLESTEROLEMIANTS ET/OU DUN AGONISTE INVERSE/ANTAGONISTE DU RECEPTEUR H3 | [2008/36] | Entry into regional phase | 28.03.2008 | National basic fee paid | 28.03.2008 | Designation fee(s) paid | 28.03.2008 | Examination fee paid | Examination procedure | 28.03.2008 | Examination requested [2008/36] | 04.09.2008 | Amendment by applicant (claims and/or description) | 27.04.2009 | Despatch of a communication from the examining division (Time limit: M06) | 19.10.2009 | Reply to a communication from the examining division | 31.03.2010 | Despatch of a communication from the examining division (Time limit: M06) | 11.10.2010 | Application deemed to be withdrawn, date of legal effect [2011/13] | 12.11.2010 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2011/13] | Fees paid | Renewal fee | 08.12.2008 | Renewal fee patent year 03 | 07.12.2009 | Renewal fee patent year 04 | 22.11.2010 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO0232893 (SCHERING CORP [US]) [Y] 1-48 * the whole document *; | [Y]WO03033488 (SCHERING CORP [US]) [Y] 1-48 * the whole document * | [Y] - KOTEISH AYMAN ET AL, "Animal models of steatohepatitis.", BEST PRACTICE & RESEARCH. CLINICAL GASTROENTEROLOGY OCT 2002, (200210), vol. 16, no. 5, ISSN 1521-6918, pages 679 - 690, XP002429939 [Y] 1-48 * the whole document * * page 686 * DOI: http://dx.doi.org/10.1053/bega.2002.0332 | [Y] - TOTH PETER P ET AL, "Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.", EXPERT OPINION ON PHARMACOTHERAPY JAN 2005, (200501), vol. 6, no. 1, ISSN 1744-7666, pages 131 - 139, XP009082392 [Y] 1-48 * abstract * * 2.2 page 133 * * 3.2 page 134 * DOI: http://dx.doi.org/10.1517/14656566.6.1.131 | [PY] - AHMED MOHAMED H ET AL, "Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6(1):131-139.", EXPERT OPINION ON DRUG SAFETY JUL 2006, (200607), vol. 5, no. 4, ISSN 1744-764X, pages 487 - 488, XP002429940 [PY] 1-48 * page 488, column 2, line 10 - line 14 * DOI: http://dx.doi.org/10.1517/14740338.5.4.487 | [Y] - FARNIER MICHEL ET AL, "Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.", EUROPEAN HEART JOURNAL MAY 2005, (200505), vol. 26, no. 9, ISSN 0195-668X, pages 897 - 905, XP002429941 [Y] 1-48 * the whole document * DOI: http://dx.doi.org/10.1093/eurheartj/ehi231 | [Y] - HANCOCK A A ET AL, "Histamine H3 antagonists in models of obesity", INFLAMMATION RESEARCH, (200403), vol. 53, no. Suppl. 1, ISSN 1023-3830, pages S47 - S48, XP002429942 [Y] 1-48 * the whole document * DOI: http://dx.doi.org/10.1007/s00011-003-0322-5 | [Y] - FEY THOMAS A ET AL, "Effects of A-423579, a Novel Histamine-3 Receptor Antagonist in Rodent Models of Diet-Induced Obesity", FASEB JOURNAL, & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; WASHINGTON, DISTRICT OF COLUMBIA, USA; APRIL 17-21, 2004, (2004), vol. 18, no. 4-5, ISSN 0892-6638, page ABST. 394.5, XP009082414 [Y] 1-48 * the whole document * |